Review
doi: 10.1016/S0065-230X(06)96009-6.
Tumor antigens as surrogate markers and targets for therapy and vaccines
Affiliations
- PMID: 17161680
- DOI: 10.1016/S0065-230X(06)96009-6
Item in Clipboard
Review
Tumor antigens as surrogate markers and targets for therapy and vaccines
Adv Cancer Res.
2007.
Abstract
There are a large number of tumor antigens, which may either be specific to the tumor or inappropriately expressed or processed (tumor-associated antigen, TAA). Over the last few years, hundreds of new TAAs have been identified. Some of these represent good targets for both passive (antibody based) and active (vaccine based) therapies. Antibody treatments targeted on tumor-specific antigens, such as Herceptin and Cetuximab, have been effective in clinical trials and are now licensed. In addition, TAAs act as good surrogate markers for use in both the diagnosis and assessment of treatment in cancer patients.
Similar articles
-
Clinical development of MVA-based therapeutic cancer vaccines.Expert Rev Vaccines. 2008 Sep;7(7):889-93. doi: 10.1586/14760584.7.7.889. Expert Rev Vaccines. 2008. PMID: 18767940 Review.
-
Cancer immunotherapy targeting the telomerase reverse transcriptase.Cell Mol Immunol. 2006 Feb;3(1):1-11. Cell Mol Immunol. 2006. PMID: 16549043 Review.
-
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12582023
-
Cancer vaccines: Where are we going?Asia Pac J Clin Oncol. 2010 Mar;6 Suppl 1:S9-15. doi: 10.1111/j.1743-7563.2010.01270.x. Asia Pac J Clin Oncol. 2010. PMID: 20482531 Review.
-
The reverse proteomics for identification of tumor antigens.J Microbiol Biotechnol. 2007 Jun;17(6):879-90. J Microbiol Biotechnol. 2007. PMID: 18050904 Review.
Cited by
-
Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence.Mol Cell Proteomics. 2012 Feb;11(2):M111.014480. doi: 10.1074/mcp.M111.014480. Epub 2011 Nov 9. Mol Cell Proteomics. 2012. PMID: 22074704 Free PMC article.
-
Carbohydrate-based cancer vaccines: target cancer with sugar bullets.Glycoconj J. 2012 Aug;29(5-6):259-71. doi: 10.1007/s10719-012-9399-9. Epub 2012 Jun 6. Glycoconj J. 2012. PMID: 22669462 Review.
-
Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review.Cancers (Basel). 2022 Aug 9;14(16):3842. doi: 10.3390/cancers14163842. Cancers (Basel). 2022. PMID: 36010836 Free PMC article. Review.
-
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.Cancer Immunol Immunother. 2007 Nov;56(11):1687-700. doi: 10.1007/s00262-007-0343-y. Epub 2007 Jun 15. Cancer Immunol Immunother. 2007. PMID: 17571260 Free PMC article. Review.
-
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7. J Immunother. 2012. PMID: 23090078 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
